The independent medical news service
15-12-2020 | Rheumatology | News | Article
ACTT-2 trial: Baricitinib shows promise for COVID-19
Adding the JAK inhibitor baricitinib to remdesivir treatment reduces recovery time and improves clinical outcomes in hospitalized patients with moderate-to-severe COVID-19, suggest findings from the ACTT-2 randomized controlled trial.
Covid 19 hospital patient/© South_agency / Getty Images / iStock, Antibodies_3D illustration/© Dr_Microbe / Getty Images / iStock